Skip to main content Skip to main navigation menu Skip to site footer

Interleukin-17 expression is associated with survival in pediatric osteosarcoma

  • Muhammad Riza ,
  • Harsono Salimo ,
  • Brian Wasita ,
  • Vitri Widyaningsih ,
  • Bambang Purwanto ,
  • Pamudji Utomo ,
  • Soestrisno Soestrisno ,
  • Fikar Arsyad Hakim ,
  • Fairuz Zahidah ,
  • Janur Wayanshakty ,


Link of Video Abstract:


Background: Osteosarcoma is a cancerous tumor that develops from bone-forming mesenchymal cells. The cause of osteosarcoma appears to be multifaceted, and cytokine production is a potential causative factor. T helper 17 cells are responsible for producing the cytokine interleukin 17 (IL-17), and its association with cancer progression remains a subject of ongoing debate. This study aimed to analyze IL-17 expression before and after neoadjuvant chemotherapy and the relationships between prognostic factors and survival.

Methods: We investigated the expression of IL-17 in osteosarcoma tissues from 22 pediatric patients who underwent neoadjuvant chemotherapy. Histopathological and immunohistochemical methods were used to assess IL-17 expression prior to the patients undergoing neoadjuvant chemotherapy. IL-17 expression before chemotherapy was classified as low or high based on the median data. Survival was calculated using the Kaplan–Meier survival analysis with the log-rank test.

Result: The following characteristics were found to be associated with longer survival: male, age > 10 years old, distal location of tumor, low-grade tumor, and tumor with no metastasis; however, there were no statistically significant differences (p > 0.05). Binary logistic analysis showed that high expression of IL-17 based on the median data before neoadjuvant chemotherapy (>1.62%) were significantly associated with reduced survival (p = 0.010). The mean estimated overall duration of survival was 19.4 months (95% confidence interval (CI): 14.5-24.3) for low IL-17 expression and 14.0 months (95%CI: 8.3–19.7) for high IL-17 expression based on the median data. There was no statistically significant difference in the overall survival (p > 0.05).

Conclusion: High expression of IL-17 before neoadjuvant chemotherapy after neoadjuvant chemotherapy were associated with poor survival among pediatric osteosarcoma patients. These findings suggest that IL-17 is a potential prognostic biomarker for pediatric osteosarcoma.


  1. SEER. Cancer Stat Facts: Bone and Joint Cancer. 2023. Available from:
  2. Rojas GA, Hubbard AK, Diessner BJ, Ribeiro KB, Spector LG. International trends in incidence of osteosarcoma (1988-2012). Int J Cancer. 2021;149(5):1044–53.
  3. Fukushima T, Ogura K, Akiyama T, Takeshita K, Kawai A. Descriptive epidemiology and outcomes of bone sarcomas in adolescent and young adult patients in Japan. BMC Musculoskelet Disord. 2018;19(1):1–8.
  4. Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database. Cancer Epidemiol. 2015;39(4):593–9.
  5. Yang B, Kang H, Fung A, Zhao H, Wang T, Ma D. The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis. Mediators Inflamm. 2014;2014:623759.
  6. de Azevedo JWV, de Medeiros Fernandes TAA, Fernandes JV, de Azevedo JCV, Lanza DCF, Bezerra CM, et al. Biology and pathogenesis of human osteosarcoma (Review). Oncol Lett. 2020;19(2):1099–116.
  7. Mikkola T, Almahmoudi R, Salo T, Al-Samadi A. Variable roles of interleukin-17F in different cancers. BMC Cancer. 2022;22(1): 54.
  8. Al-Samadi A, Moossavi S, Salem A, Sotoudeh M, Tuovinen SM, Konttinen YT, et al. Distinctive expression pattern of interleukin-17 cytokine family members in colorectal cancer. Tumor Biology. 2016;37(2):1609–15.
  9. Liu Y, Sun X, Zhao X, An L, Wang Z, Jiang J, et al. Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. Pathol Res Pract. 2018;214(4):482–91.
  10. Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17f in colon tumorigenesis. PLoS One. 2012;7(4): e34959.
  11. Chen Y, Yang Z, Wu D, Min Z, Quan Y. Upregulation of interleukin-17F in colorectal cancer promotes tumor invasion by inducing epithelial-mesenchymal transition. Oncol Rep. 2019;42(3):1141–8.
  12. Li C, Ma X, Tan C, Fang H, Sun Y, Gai X. IL-17F expression correlates with clinicopathologic factors and biological markers in non-small cell lung cancer. Pathol Res Pract. 2019;215(10): 152562.
  13. Yang D, Zhou J, Zeng T, Yang Z, Wang X, Hu J, et al. Serum chemokine network correlates with chemotherapy in non-small cell lung cancer. Cancer Lett. 2015;365(1):57–67.
  14. Xiang C, Zha Y, Chen Q. Effect of radiotherapy and chemotherapy on levels of serum S100B, IL-6, and IL-17 in patients with malignant glioma. European Journal of Inflammation. 2018;16.
  15. Gaba FM, Mbengue B, Diop M, Diouf D, Ka S, Niang DGM, et al. Predictive significance of IL-17A serum levels during chemotherapy in Senegalese women with cervical cancer. Open J Immunol. 2019;09(04):37–47.
  16. Song Y, Yang M, Zhang H, Sun Y, Tao Y, Li H, et al. IL-17 Affects the progression, metastasis, and recurrence of laryngeal cancer via the inhibition of apoptosis through activation of the PI3K/AKT/FAS/FASL pathways. J Immunol Res. 2020;2020:2953191.
  17. Zhao J, Chen X, Herjan T, Li X. The role of interleukin-17 in tumor development and progression. Journal of Experimental Medicine. 2020;217(1): e20190297.
  18. Sui G, Qiu Y, Yu H, Kong Q, Zhen B. Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer. Oncol Lett. 2019;17(1):944–50.
  19. Lee MH, Tung-Chieh Chang J, Liao CT, Chen YS, Kuo ML, Shen CR. Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients. Oncotarget. 2018;9(11):9825-37.
  20. Wang XF, Zhu YT, Wang JJ, Zeng DX, Mu CY, Chen Y Bin, et al. The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients. PLoS One. 2017;12(9): e0185168.
  21. Ariyana, Prihantono P, Idris I, Ahmad M. Serum interleukin-17 (IL-17) level in breast carcinoma before and after chemotherapy. Medicina Clinica Practica. 2020;3:100093.
  22. Wang M, Wang L, Ren T, Xu L, Wen Z. IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells. Cancer Biol Ther. 2013;14(2):155–63.
  23. Song L, Ma S, Chen L, Miao L, Tao M, Liu H. Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer. Cancer Sci. 2019;110(7):2100–9.
  24. Punt S, Langenhoff JM, Putter H, Fleuren GJ, Gorter A, Jordanova ES. The correlations between IL-17 vs. Th17 cells and cancer patient survival: A systematic review. Oncoimmunology. 2015;4(2):1–10.
  25. Zhang X, Weng W, Xu W, Wang Y, Yu W, Tang X, et al. Prognostic significance of interleukin 17 in cancer: a meta-analysis. Int J Clin Exp Med. 2014;7(10):3258-69.

How to Cite

Riza, M. ., Salimo, H. ., Wasita, B. ., Widyaningsih, V. ., Purwanto, B. ., Utomo, P. ., Soestrisno, S., Hakim, F. A. ., Zahidah, F. ., & Wayanshakty, J. . (2023). Interleukin-17 expression is associated with survival in pediatric osteosarcoma. Bali Medical Journal, 13(1), 270–277.




Search Panel